CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Not applicable	2025-02-27		NCT06850285

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanxi Bethune Hospital	33

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Shanxi Bethune Hospital	Taiyuan	China	1

Clinical trials